Anti-infective therapy using species-specific activators of Staphylococcus aureus ClpP

Abstract

The development of selective ClpP activators targeting only the MRSA isolates without interfering with the human variant is currently challenging. Here, the authors report on the structure-based design of enantiomers of ZG197 and identify the discriminator factor between the proteins.